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Purpose: The purpose of this project was to investigate gene regulation of a predetermined 
panel of apoptotic genes in murine renal cortex after treatment with 177Lu-octreotate 
after one day and seven days.  
Theory: The kidneys and bone marrow are the risk organs in 177Lu-octreotate treatment, but by 
fractioning the treatment the bone marrow recovers. This leads to the kidneys being 
the dose-limiting risk organ. Apoptosis is a known effect after irradiation of cells and 
can result in nephrotoxicity after treatment. Whether apoptosis is initiated or inhibited 
after irradiation depends on a balance of pro-apoptotic and anti-apoptotic signals in 
the cells and is controlled by many genes divided into gene families. By analysing the 
expression of apoptotic genes, information about the induction or inhibition of 
apoptosis can be obtained. The absorbed dose is calculated in order to relate the 
responses in the tissue to irradiation by 177Lu. The renal cortex receives a higher 
absorbed dose after treatment with 177Lu-octreotate and is therefore of high interest 
when studying apoptosis.  
 
Method: RNA from the kidney cortex of 12 different mice was used for the analysis. The mice 
were divided into two irradiated and two control groups and killed at one or seven 
days after administration of 150 MBq 177Lu-octreotate or physiological saline, 
respectively. A panel of both pro-apoptotic and anti-apoptotic genes was investigated 
with a quantitative real-time polymerase chain reaction (QPCR) array. Prior to this, 
the RNA-concentration was determined with the Qubit ® assay in order to use the 
same amount of RNA in the QPCR assay. The absorbed dose in the kidney cortex was 
calculated for each mouse in the irradiated groups and the transcriptional response 
was related to the absorbed dose and time of irradiation. 
 
Result: The group that received a lower absorbed dose and was killed after one day (group 1) 
showed a higher increase in transcriptional response to irradiation than the group 
killed after seven days (group 2). The regulation in group 1 indicated pro-apoptotic 
responses in the renal cortex, wheras in group 2, a shift to anti-apoptotic responses 
was observed.  
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Neuroendocrine cells regulate, store and release hormones through signals from the central 
nervous system. When malignant, neuroendocrine tumours (NET) have an overexpression of 
somatostatin receptors on the cell membrane compared to normal tissue. 
 
These tumours are often treated with the radiopharmaceutical 177Lu-octreotate, which is a form 
of targeted radiotherapy. Treatment with targeted radiotherapy is designed so that the carrier 
molecule of the radionuclide has characteristics that leads to the radiopharmaceutical binding 
to the tumour in greater extent than to normal tissue cells. Octreotate is a somatostatin analogue, 
i.e. octreotate is structurally similar to somatostatin. This will lead to the radiopharmaceutical 
to bind to the receptors and deliver a radiation dose. Because of the therapy being designed to 
target the characteristics of the tumour cell, and being administrated systematically, it is 
possible to treat metastases.  
 
177Lu is a suitable radionuclide for NET therapy due to its relatively low beta energy (mean 
energy of 147 keV per decay) and low emission of gamma photons in comparison to other 
radionuclides [1, 2]. When using a radionuclide for therapy, the aim is to have a high emission 
of electrons and low emission of photons. The electrons deposit energy within a certain range, 
leading it to being of the same proportions as the average size of metastases, which gives a local 
absorbed dose [2]. This is the purpose of the therapy due to the carrier molecule being targeted 
to the tumour cell. Photons have no range and will thus expose all tissues of the body. The 
photon emission from 177Lu can be used in imaging with single-photon emission computed 
tomography (SPECT) after treatment.  
 
The kidneys and the bone marrow become the primary risk organs with 177Lu-octreotate therapy 
[3]. Fractionated therapy allows the bone marrow to recover which makes the kidneys the dose 
limiting organ. The objective is to give the tumour as high radiation dose as possible, but at the 
same time to spare the kidneys from radiation induced renal toxicity [4-6]. When injecting a 
radiopharmaceutical to the bloodstream, the molecule will accumulate in different organs apart 
from the tumour to a different extent. This is depending on the characteristics of the organ and 
the radiopharmaceutical. A fraction of the administered activity stays in the kidneys in 177Lu-
octreotate treatment. The amount of radioactivity accumulating in the kidneys varies between 
individuals [1, 3, 7, 8]. The kidneys become a risk organ when treating tumours with 177Lu-
octreotate because of its role in the body, which is cleaning the blood from waste products by 
filtrating the blood. When the primary urine is reabsorbed in the proximal tubuli, an amount of 
177Lu will stay in the kidney and deliver a radiation dose [6, 8]. 
 
It is necessary to estimate the absorbed dose from 177Lu in a tissue in order to relate biological 
effects to the treatment such as gene expression changes or other clinical parameters. Since the 
amount of 177Lu-octreotate that remains in the kidneys differs between each individual, the 





Several studies of irradiation of the kidney through treatments with radiolabelled somatostatin 
analogues showed that the dose distribution within the kidney is heterogeneous, leading to a 
higher uptake of the radiopharmaceutical in the cortex of the kidney compared to medulla [9, 
10]. This makes the cortex a tissue of interest in the kidney when studying apoptosis as an effect 
of irradiation. There is also an interest in studying the impact that time has on the apoptotic 
burden, due to the differential biodistribution of the radiopharmaceutical in the kidney and 
increased absorbed dose (protracted irradiation). The absorbed dose in an organ after injection 
of a radiopharmaceutical is dependent of the retention in the organ, but also on the half-life of 
the radionuclide.  
 
When irradiated, cells can undergo apoptosis as a major response to irradiation [9]. This 
happens when a cell’s DNA is damaged to an extent when it cannot be repaired. Depending on 
the type of cell, it can be one of the most common cell death mechanism after irradiation [8]. 
Apoptosis in the kidneys has been shown to correlate with kidney damages resulting in critical 
loss of kidney functions [4, 5, 10]. 
Apoptosis, in comparison to necrosis, is a process that involves a large number of genes, divided 
into gene families. The genes play different roles in producing proteins that activate caspases. 
Caspases are enzymes that fragmentate the cell, causing no inflammation or leakage outside of 
the cell [11, 12], see figure 1 for example. 
 
 
Figure 1: A prostate cancer cell undergoing apoptosis and being fragmentated into apoptotic bodies. 
Image from Egelberg’s own work [13]. 
 
Whether the cell lives or dies through apoptosis is a balance between signals inhibiting 
apoptosis and activating it. Apoptosis can be triggered either from intrinsic or extrinsic 
pathways, by activation of pro-apoptotic genes or lack of anti-apoptotic genes [9, 11]. Apoptosis 
is initiated through the extrinsic pathway by signalling molcules from outside of the cell that 
bind to death receptors. These death receptors belong to a gene superfamily called tumour 
necrosis factor superfamily (TNF). The activation of these death receptors occurs via their death 




Bcl-2 gene family, in turn activating the mitochondrial pathway, which also plays a role in 
apoptosis through intrinsic stimuli. 
Caspase 8 can also activate effector caspases (caspase 3, 6 and 7), which directly fragment the 
different parts of the cell [9, 11]. Another class of caspases are initiator caspases that have the 
function of activating the effector caspases, which creates a chain reaction resulting in the 
execution of apoptosis. 
Caspases normally exist in cells as an inactive form (procaspases) and are cleaved to their active 
form following release of different pro-apoptotic proteins.  
 
Intrinsic activation of apoptosis can be triggered by several different processes within the cell; 
either by the activation of pro-apoptotic factors through e.g. radiation, or the lack of anti-
apoptotic factors, activating the effector caspases [11]. When irradiated, the DNA of the cell is 
damaged either through direct or indirect damage to the molecule, the ratio of which depending 
on the type of radiation and other physical properties. Radiation through charged particles 
causes mainly direct damage by single or double strand breaks. Photon irradiation creates free 
radicals, which in turn damages the DNA [14]. DNA damage can be repaired, but if the lesions 
are too complex or repair is error-prone, the cell may accumulate deleterious effects (e.g. 
mutations, loss of genetic material or chromosomal rearrangement) which can lead to 
carcinogenesis. If the damage burden is too high, the cell usually undergoes apoptosis instead 
of initiating repair. Whether or not a cell’s damages are repaired is controlled to a great extent 
by the gene p53. 
 
When the intrinsic pathway is activated, the mitochondria are stimulated through a change in 
the trans-membrane potential, disturbing its function, which in turn makes the mitochondria 
release cytochrome c, activating the effector caspases [9, 11]. The genes involved in the 
intrinsic pathway, controlling the mitochondrial release of pro-apoptotic signals are mainly 
from the Bcl-2 family and p53, which activates certain gene groups in the Bcl-2 gene family 
[9, 11]. P53 is an important gene in regulation of apoptosis, since its activation plays a crucial 
role in the processes following irradiation. It activates transcription of genes for DNA repair, 
or of certain pro-apoptotic genes and inhibits transcription of anti-apoptotic genes.  
 
When either of the two means of activation of apoptosis occurs, the mitochondria are 
responsible for releasing apoptosis-inducing proteins into the cell, such as cytochrome c, which 
in turn activate caspase 9 and then the effector caspases [9, 11, 12].  
These different types of activation of apoptosis are controlled and balanced through different 
gene families, where an activation or suppression of these genes can give information about the 
balance between pro-apoptotic and anti-apoptotic signals following irradiation. By analysing 
genes that give signals for suppressing or activating apoptosis, information about the processes 
that take place in the cell related to apoptosis can be obtained. 
 
When a gene gets expressed, DNA is first transcribed to RNA. This messenger RNA (mRNA) 
serves as a template for the translation to a specific protein. The occurrence of mRNA related 





A method of investigating differential gene expression is the quantitative real-time polymerase 
chain reaction (QPCR) assay. QPCR uses complementary DNA (cDNA) which is synthesized 
from RNA to analyse whether a gene is up- or down-regulated, compared to a control sample. 
The target genes are normalised with reference genes, which should show no up- or down-
regulation irrespective of treatment [15].  
Reverse transcription is the process of creating cDNA from RNA samples. A primer (a short 
sequence of nucleotides) binds to the mRNA, which enables the enzyme reverse transcriptase 
to bind to the location of the double strand. Reverse transcriptase adds nucleotides- creating the 
complementary DNA sequence to the mRNA. After reverse transcription, the RNA is 
denaturised, and the single-stranded cDNA is used for the QPCR assay [16]. By analysing the 
differential regulation of genes involved in apoptosis using QPCR, considering both pro-
apoptotic and anti-apoptotic genes, information about the induction or inhibition of apoptosis 
in a tissue can be obtained after irradiation with 177Lu. Analysis with QPCR shows early 






The purpose of this study was to investigate the expression of a panel of genes involved in 
apoptosis in the kidney cortex of mice that had been treated with 177Lu-octrotate at two different 
times after injection. The absorbed dose to the kidney cortex was also calculated in order to 
relate the gene expression to the absorbed dose. 








Materials and methods 
Animal experiment 
 
Prior to this study, an animal experiment was performed to obtain mRNA-samples and activity 
data for this project. For the experiment, 12 female C57BL mice were used, divided into four 
groups, two control groups and two irradiated groups. The irradiated groups were i.v. injected 
with 0.1 ml 150 MBq 177Lu-octreotate and the other two control groups with the same volume 
of a physiological saline solution. Two of the groups were killed (treated and control) after one 
day and the other two groups after seven days.  
After killing the mice, one of the kidneys was excised and the activity in the entire kidney was 
measured in a gamma counter (2480 Wizard Automatic Gamma Counter, PerkinElmer). The 
other kidney was frozen in liquid nitrogen. Cortical and medullary tissue samples were 
dissected on dry ice and respective samples subjected to extraction of total RNA. RNA samples 
from the kidney cortex were used for this study, see figure 2. 
 
Figure 2: Schematic picture of the workflow prior to this project (panel A) and during the project (panel 







In order to calculate the absorbed dose, the MIRD-formalism was used according to the 




    (1) 
 
Where ?̃?𝑘𝑖𝑑𝑛𝑒𝑦 was the activity in the kidney integrated over time, ∑ 𝑛𝑖𝐸𝑖  the mean beta energy 
per decay, ignoring the photon energies,  Φ𝑖  the absorbed fracion and 𝑚𝑖  the mass of the 
kidney.  
The time-integrated activity was calculated with a trapezoid function in MATLAB, with the 
initial activity 𝐴(0) = 0 𝐵𝑞.   
The activity was measured with a gamma counter as counts per minute (CPM). In order to 
obtain the measurement results in Bq, a calibration of the gamma counter was performed. A 
sample with 177Lu was measured with a well-type ionization chamber (CRC-15R, Capintec, 
Ramsey, New Jersey, USA) and solutions with eight different activities varying from 6.25 kBq 
up to 800 kBq were prepared. Six samples were prepared with the same activity and measured 
in the gamma counter. The mean CPM per activity was calculated and plotted, where a linear 
fit was made where the plot was linear. Dead time and background corrections were made 
before plotting the activities. The slope from the linear fit gave the calibration factor. The CPM 
obtained for each kidney was divided by the calibration factor, giving the activity in each 
kidney. 
Data for the activity concentration in the kidney up to the point of killing was taken from a 
previous study [19] investigating the biodistribution in different organs at different times from 
injection. The activity concentration was multiplied by the injected activity and the mass of 
each kidney. A time correction between measurement of the activity and killing was made. This 
gave a set of discreet values for the total activity in the entire kidney for specific times up to the 
killing.  
Data for the fraction of energy absorbed by the renal cortex was considered for the entire kidney 
as a source organ and taken from literature [20]. The mean beta energy emitted from 177Lu is 
147 keV per decay [1].  






Gene expression analysis 
 
Before the reverse transcription and the QPCR assay was performed, the concentration of the 
total RNA was analysed. The analysis was performed with Qubit (Qubit ® RNA BR Assay Kit, 
molecular probes, Life technologies) to ensure that the same amount of RNA was used for the 
different samples. For the cDNA synthesis, 110 ng of RNA was used for each replicate. 
The mRNA was synthesised to cDNA using the RT2 First Strand Kit from QIAGEN (RT2 First 
Strand Kit, 330404, QIAGEN). A Genomic DNA elimination mix was prepared, containing 
110 ng RNA, 2 µL Buffer Ge and RNase free water up to 11 µL. The mix was incubated for 
five minutes at 45 °C and placed in ice for one minute. Afterwards, it was combined with a 
Reverse transcription mix, consisting of 4 µL 5x Buffer BC3, 1 µL Control P2, 2 µL RE3 
Reverse Transcription Mix and 3 µL RNase free water. The Genomic DNA elimination mix 
and Reverse transcription mix were incubated at 42 °C for 15 minutes, allowing the reverse 
transcription to take place, then five minutes at 95 °C to denaturate the mRNA. 91 µL of RNase 
free water was added and the aliquots frozen at -20 °C until used for the QPCR assay. 
The QPCR assay was performed using an array investigating 84 different genes related to 
apoptosis, 5 control genes and technical controls (Appendix) from QIAGEN (RT2 PCR Profiler 
Array, Mouse Apoptosis, PAMM-012ZC, QIAGEN), using the RT2 SYBR Green ROX qPCR 
Mastermix (QIAGEN). The cDNA was pipetted as 102 µL aliquots into the reaction mastermix 
and was added with 20 µL per well. The plate was analysed using a 7500 Fast Real-Time PCR 
system (Applied Biosystems). For two biological samples (group 1 and control group 1, mouse 
no.1 and control 1), the analysis was performed with a 7500 Real-Time PCR system (Applied 
Biosystems) with a different plate format (RT2 PCR Profiler Array, Mouse Apoptosis, PAMM-
012ZA, QIAGEN). Three plates per sample were analysed to achieve technical replicates. 
QPCR works through a sequence-specific primer that binds to the gene of interest through the 
annealing. In addition, nucleotide probes, carrying a fluorescent dye and a quencher, bind to a 
certain sequence of the amplicon (amplified sequence section of the cDNA (gene) of interest). 
The reaction buffer contains nucleotides, salts and DNA polymerase. The QPCR reaction takes 
place by changing the temperature through three cycles and repeating the cycles around 40 
times. Prior, an initialization step is required for hot-start DNA polymerase to be activated, 
where the temperature is around 95°C for 10 minutes. 
 
The QPCR cycles go through three different phases, the stationary baseline phase, the 
exponential phase and the plateau phase, see figure 3. The stationary baseline, also called the 
lag phase, is when the concentration of PCR products is slowly increasing, but there is not 
enough fluorescence produced to be detected, or the consistency of the reaction is not fully 
exponential yet. This is where the baseline is set. In the exponential phase, the doubling of the 
amplicon is consistent and ongoing, and there is a large surplus of reagents available for the 
exponential chain reaction to continue. In the linear phase, there are fewer reagents left due to 
consumption in previous cycles, which causes a decrease in the slope of the fluorescence curve. 






Figure 3: Representative illustration of the different phases of the fluorescence curve in QPCR. The 
threshold cycle (Ct-value) is marked for each gene with a straight line. 
 
By measuring the cycle where the reaction becomes exponential, information about the 
expression level of the gene is obtained and quantification is possible [16]. This quantity is 
called the threshold cycle, Ct. The quantification of the expression level is obtained by 
normalising the Ct-value of the gene of interest to several control genes and by subtracting the 
normalised Ct-values of the irradiated group (ΔCt irr.), with that of the control group (ΔCt ctrl). 
This is used to calculate the fold change (FC), which gives the gene regulation by: 
 
∆𝐶𝑡 𝑖𝑟𝑟. = 𝐶𝑡 𝑖𝑟𝑟.  𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 − 𝐶𝑡 𝑖𝑟𝑟.  𝑟𝑒𝑓.𝑔𝑒𝑛𝑒 (2) 
 
∆𝐶𝑡 𝑐𝑡𝑟𝑙 = 𝐶𝑡 𝑐𝑡𝑟𝑙.𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒 − 𝐶𝑡 𝑐𝑡𝑟𝑙.𝑟𝑒𝑓.𝑔𝑒𝑛𝑒 (3) 
 
∆∆𝐶𝑡 =  ∆𝐶𝑡 𝑖𝑟𝑟. − ∆𝐶𝑡 𝑐𝑡𝑟𝑙. (4) 
 
𝐹𝐶 = 2−∆∆𝐶𝑡 (5) 
  








The absorbed dose to the kidney cortex over one day (group 1) was 20 Gy (± 0.56 Gy SD) and 
over seven days (group 2) 51 Gy (± 0.11 Gy SD). The individual absorbed dose was calculated 
for each mouse and the mean value for all the mice in the group was used when analysing gene 
expression in correlation with the absorbed dose. The activity concentration at different time 
points up to the killing is shown in table 1 and figure 4. 
Table 1: Activity concentration in the kidney up to the time of the killing [19]. 







24 7.2 (from measurement in group 1) 
72 2.8 
168 0.3 (from measurement) 
 
 
Figure 4: The activity concentration for mouse 1 in group 2 up to the time of killing. The data from 
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Table 2: Absorbed doses to the kidney cortex for each mouse and mean absorbed dose in the 
two different irradiated groups. 
Mouse Absorbed dose 
Group 1 [Gy] 
Absorbed dose 
Group 2 [Gy] 
1 19 51 
2 19 51 
3 20 51 




In total, 16 genes were significantly regulated in at least one of the irradiated groups, see figure 
5 and 6 (see Appendix for regulation of all genes). Twelve genes were regulated in group 1 and 
eight genes in group 2. In each group, both pro-apoptotic and anti-apoptotic gene regulation 
was observed. For the majority of the array-based genes, no significant regulation was detected. 
The majority of the pro-apoptotic genes that were significantly regulated were upregulated. 
However, two pro-apoptotic genes (Cidea and Bok), were downregulated in group 1 and group 
2 (Fasl and Casp1). The anti-apoptotic genes were in majority downregulated with the 
exception for il10, which was significantly upregulated in group 2. In the group that was killed 
after one day (group 1), the regulation of seven genes indicated the initiation of apoptosis, two 
genes indicated inhibition and two genes were regulated that could lead to both regulations of 
apoptosis. In group 2, four genes indicated activation, three genes inhibition of apoptosis and 





Pro-apoptotic Cd70     Traf2     Igf1r     
Abl1     Cideb     Traf3     Il10     
Aifm1     Cradd     Trp53bp2     Lhx4     
Anxa5     Dapk1     Anti-apoptotic Mcl1     
Apaf1     Dffa     Api5     Naip1     
Bad     Dffb     Atf5     Naip2     
Bak1     Diablo     Bag1     Nfkb1     
Bax     Fadd     Bag3     Nme5     
Bcl2l11     Fas     Bcl2     Nol3     
Bid     Gadd45a     Bcl2a1a     Polb     
Bok     Fasl     Bcl2l1     Prdx2     
Casp1     Ltbr     Bcl2l10     Trp63     
Casp12     Mapk1     Bcl2l2     Trp73     
Casp14     Nod1     Birc2     Xiap     
Casp2     Pycard     Birc3     Both 
Casp3     Ripk1     Birc5     Akt1     
Casp4     Tnfrsf10b     Bnip2     Bcl10     
Casp6     Tnfrsf11b     Card10     Bnip3     
Casp7     Tnfrsf1a     Cd40lg     Bnip3l     
Casp8     Tnfsf10     Cflar     Tnf     
Casp9     Tnfsf12     Cidea     Trp53     
Cd40     Traf1     Dad1        
 
Figure 5: Overview of apoptosis-related gene regulation. First column shows results for group 1, second 
for group 2. Green indicates significant upregulation, orange significant downregulation, and white no 
significant regulation. Yellow for the gene Lhx4 indicates no results. 
Figure 6: Significant gene regulation in group 1 and 2. Bars represent fold change values with error bars 
(SEM) for both biological and technical replicates. The horizontal lines represent a fold change of 1.5, 
indicating significance. 
Apaf1 Bax Bcl2l10 Bok Cidea Fas Tnfrsf10b Tnfsf10 Trp73 Casp1 Fasl Bcl2a1a Birc5 Bag3 il10 Cd40lg Tnf
Pro-apoptotic Anti-apoptotic Both
1 day (20 Gy) 2,22 2,62 3,82 -1,77 -7 1,67 6,13 -1,55 2,68 -1,49 -1,4 -1,3 -1,51 -1,6 1,31 -2,32 -3,28


























Fold change group 1 and group 2




One of the control genes, Gusb, showed an increased expression relative to other control genes 
and was not used when normalizing the Ct-values. The reaction failed for Lhx4, so this gene 
was not considered in this study. 
The error bars in figure 7 shows the uncertainties for both the biological and technical replicates, 
meaning that SEM was calculated for all of the analysed arrays for each gene. The difference 
between these uncertainties are illustrated for two genes, Cd40lg and Tnfrsf10b. In this figure, 
the individual gene regulation is presented with SEM as error bars. 
 
 
Figure 7: The gene regulation of Cd40lg and Tnfrsf10b for each mouse in group 1 and 2, respectively 
with error bars (SEM). The mice are represented as either group 1 that was killed after one day or group 









Individual fold change for genes Cd40lg and 
Tnfrsf10b 
1d m1 1d m2 1d m3 7d m1 7d m2 7d m3





In this project, the regulation of 84 different genes related to apoptosis were investigated after 
one and seven days for different absorbed doses from 177Lu. 46 of the genes in the QPCR array 
were pro-apoptotic, 32 anti-apoptotic and six genes can be considered both pro- and anti-
apoptotic. This unequal ratio mean that an overrepresentation of pro-apoptotic genes was 
investigated. Only regarding statistics, this may give more information about whether apoptosis 
was initiated than inhibited. However, since anti-apoptotic genes represented almost 40 % of 
the panel, the results from the assay still give a clear image of the inhibition of apoptosis on a 
transcriptional level. Moreover, a direct interpretation by number of genes is not feasible in 
general, since gene products function in pathways where they can have differential impact on 
signal transduction and outcome. A direct comparison between treatment groups, however, is 
possible within the frame of the panel irrespective of these considerations. A clear trend of gene 
regulation indicating the occurrence of apoptosis appeared. An upregulation of pro-apoptotic 
genes and a downregulation of anti-apoptotic genes was found for both groups. Five of the 16 
genes were significantly regulated in both groups. When studying a gene expression, it is 
important consider which genes interact in the same pathway in order to understand gene 
regulation in the context of cellular function and outcomes. 
Overall, the group that was killed after one day showed an increased regulation in comparison 
to the group killed after seven days. The genes regulated in both groups indicate that the cells 
are signalling for apoptosis to be induced. When irradiating cells, there is often an early 
response in gene expression signalling for several processes that respond later, including 
signalling pathways for apoptosis. Apoptosis is a process that depends on the balance between 
proteins that inhibit apoptosis and proteins that activate it, and thus can be considered a late 
response to irradiation [14]. A late responding process is dependent of the synthesis of early 
responding genes. 
In this study, there is a difference in the absorbed dose for the different groups, but also a 
difference in time between killing the mice. The results indicate that apoptosis-related 
regulation in the kidney cortex occurs as a response to an absorbed dose of 20 Gy protracted 
over 24 hours, mostly by an upregulation of pro-apoptotic genes, and after a prolonged absorbed 
dose of 51 Gy over seven days by a downregulation of anti-apoptotic genes. The slight 
downregulation of anti-apoptotic genes after seven days indicates a shift in the biological 
response over time. Since the former is not very pronounced considering the overall panel and 
possible pro-apoptotic regulation, a shift towards survival after seven days can be assumed. The 
results from this study do not show if the cells in the renal cortex undergo apoptosis, only 
indication towards a pro-apoptotic response. This means that if apoptosis occurs in the cells 
within a few days after irradiation, then the transcriptional regulation after seven days would 
indicate a shift towards pro-survival signalling. 
These results are dependent on both absorbed dose and time of investigation. It is likely to 
assume that at higher dose would increase pro-apoptotic gene regulation, whereas a longer time 
period would reflect the tissue’s response to the (initial) stressor. In addition, the time it takes 




expression results over time. This means that a change of transcriptional regulation may take 
hours until a change in protein expression may be observed. The change in protein expression 
in turn can take up to days until an effect on respective cellular processes can be observed. In 
addition, such changes may not manifest as acute responses but only after prolonged periods. 
In order to investigate the differential contribution of these factors independently, additional 
studies need to be designed in the future. 
The gene Apaf1 is a pro-apoptotic gene, encoding a protein that binds to cytochrome c, which 
activates procaspase 9, leading to the active form of the initiator caspase 9 and activation of the 
effector caspases. Apaf1 is significantly upregulated after one day (group 1). Bax is a pro-
apoptotic member of the Bcl-2 family and regulates the release of cytochrome c from the 
mitochondria. The upregulation of the Bax gene is an indicator of an increased level of 
cytochrome c in the cell [14].In mice, the protein encoded by Bcl2l10 interacts with Apaf1 and 
plays a role in apoptosis activated by caspase 9 [21]. Hence, this upregulation is in agreement 
with the regulation of Apaf1.  
Fas, Fasl (Fas Ligand), Tnfsf10 and Tnfrsf10b are members of the Tnf receptor superfamily 
and are pro-apoptotic. The activation of the FAS/FASL signalling pathway leads to apoptosis 
by forming signals activating a death domain, caspase 8 and caspase 3, leading to a chain 
reaction that executes of apoptosis. The TNFRSF10B/TNFSF10 signalling pathway activates 
caspase 3 and caspase 8 and is pro-apoptotic. The upregulation of the receptor Tnfrsf10b in 
combination with the downregulation of the ligand Tnfsf10l is counterintuitive. This may 
indicate that the receptor and ligand do not interact in equal proportion (as more receptors may 
be recruited into the binding complex) or that it is a measure to fine-tune this signalling 
pathway. It may also mean that this signalling pathway is not (fully) activated in the cells; or 
that there is still enough Tnfsf10-protein in the cell for sufficient receptor binding to activate 
the signalling pathway. This pathway should be further investigated in future studies. 
Bok is a pro-apoptotic member of the Bcl2 gene family, and even though it is downregulated in 
the kidney cortex, apoptosis can still be induced through other pathways controlled by other 
genes. Cidea is also pro-apoptotic and downregulated in group 1, interestingly, the baseline 
expression of the protein is very low in the kidneys, i.e. it is mainly expressed in soft tissue and 
breast tissue in humans [22]. 
Trp73 is a gene found in mice and is a member if the p53 family and transactivates the p53-
pathway which can activate apoptosis or cell cycle arrest (where the cell stops in its current 
state of the cell cycle, inhibiting mitosis and allowing reparations) [23]. The regulation of this 
gene is not a direct indication of apoptosis in the cell, meaning that in order to relate this 
expression to a biological response, investigation of other genes or proteins is necessary. 
Tnf belongs to the Tnf superfamily and encodes a protein that can be a part of different processes 
in the cell depending on which receptor it binds to, including apoptosis. The translation of Tnf 
can either activate the signalling pathway NF-κB, an anti-apoptotic protein complex, or a 
signalling complex cleaving procaspase 8 into its active form (caspase 8) starting the process 
of apoptosis. Hence, the up- and down regulation of this gene in the mice can be both a pro-




Cd40lg is also a member of the Tnf receptor superfamily and the protein regulates immune 
responses in the cell, either activating macrophages, B-cells or a step in a process that recruits 
leucocytes. When irradiated, the cells in the tissue can become inflamed, signalling to the bone 
marrow to initiate an immune response [24]. The immune response in the irradiated tissue in 
this study could also be caused by the cells undergoing apoptosis. Following the fragmentation 
of the cell, immune cells are recruited to phagocytize the apoptotic bodies [14]. The immune 
response by regulation of Cd40lg in the mice could be a direct effect of apoptosis or a response 
from inflammation caused by radiation.  
When performing the QPCR assay, there were no reliable results for the gene Lhx4. This could 
be caused by different reasons. The primer could be located between two exons and be sensitive 
to different splicing variants; if the specific variant of the mRNA in this study does not match 
the primer, it cannot bind and start adding nucleotides. There is a possibility that the conditions 
for the amplicon were poorly adapted for this particular primer. The primer could also have 
difficulties binding to the cDNA due to suboptimal sequence homology, which prevented it 
from ever reaching the exponential phase, thus giving a false negative.  
The results from the QPCR assay give an indication of the occurrence of apoptosis on the first 
stage of gene expression (transcription). It should be noted that the amount of mRNA in the cell 
is not in direct proportion to the protein level. The translation rate can differ between different 
genes and the same amount of mRNA of two different genes may not lead to the same amount 
of protein. There can also be an inhibition of translation by e.g. small interfering RNA 
molecules (siRNA) that degrade mRNA, or by so-called microRNA (miRNA) that bind to the 
mRNA and block translation by ribosomes (and thus building of a peptide chain).Another factor 
that may influence the apoptotic fate could be the occurrence of signals to degrade existing 
proteins in the cell, thus lowering the amount and the functional impact. Nevertheless, the gene 
expression assay shows that the cells are transcribing genes for pro-apoptotic proteins and 
suppressing anti-apoptotic ones. 
The analysis used total RNA from cortical tissue samples and not individual cells, hence, the 
results do not reflect apoptotic regulation in individual cells. Another study analysing the tissue 
for apoptotic cells needs to be done in order to establish if the cells in the tissue undergo 
apoptosis after irradiation with 177Lu-octreotate. 
In a previous study by Kristiansson et.al. [25], the gene regulation was studied in the entire 
kidney for a different mouse strain, Balb/c nude mice. These mice have a genetic mutation 
making them unable to produce T-cells and therefore have an immunodeficiency. The same 
type of QPCR array and standard cycle protocol were used in this study rendering technical 
bias unlikely. However, Kristiansson et.al. only used one control gene to normalise the results, 
in contrast to our study where four control genes were used. In addition, Kristiansson et.al. 
pooled all samples within a group, meaning that information about biological variation and 
respective standard deviation was not obtained. In their study, the four genes that showed the 
greatest regulation, Tnfrsf10b, Bax, Gadd45a and Bcl2l1, were analysed with individual 
samples of each group, as in comparison to this study where all cortex samples were analysed 




was observed as well, but no significant regulation for Gadd45a and Bcl2l1. The differences in 
the genes that were not regulated could be a result of the use of a different mouse strain, as well 
as the fact that the QPCR assay was performed with pooled groups and for the entire kidney, 
masking some gene expression as an effect of “watering down” potentially significant 
regulation.  
In the study by Schüler et.al. [19] the kidney medulla showed to have an increased number of 
regulated genes compared to the kidney cortex, even though cortex received a higher absorbed 
dose compared to medulla [7, 8]. The genes analysed in that study were not only related to 
apoptosis, meaning that some of the genes that were regulated in medulla could be connected 
to different biological processes. In this project, we analysed the kidney cortex since it receives 
a higher absorbed dose than medulla and is therefore of great interest when studying apoptosis. 
However, future studies analysing kidney medulla are needed in order to compare the difference 
in apoptotic burden between the tissues. However, a previous study has shown that an 
administration of 150 MBq of 177Lu-octreotate in mice leads to damages to the kidneys in mice 
after eight months [26].  
When calculating the absorbed dose, several assumptions need to be made. The data that is 
obtained when performing the study is the weight of the entire kidney and the activity in the 
form of CPM. In order to calculate the absorbed dose, additional information is needed; the 
absorbed fraction in the kidney cortex, the biodistribution at different times after injection and 
the weight of the cortex in proportion to the kidney were obtained from previous projects [19, 
20]. Assumptions are necessary when adapting these data, which creates uncertainties in the 
absorbed dose calculation, since the parameters in the previous studies do not precisely match 
the parameters in this project. In the work of Svensson et.al. [20], the data for absorbed fraction 
and the mass of the cortex in proportion to the kidney was taken for kidneys weighing 0.15 
grams, and the kidneys in this project weighed between 0.09 grams and 0.13 grams. The 
importance of this difference is unclear, but in Svensson’s study, a noticeable difference 
between kidneys weighing 0.15 grams and 0.20 was observed, where a smaller kidney leads to 
a higher absorbed dose. Another assumption that might influence the results of the absorbed 
dose was the use of biodistribution data from Schüler et.al. [19]. The data used for 
biodistribution was taken from mice injected with 15 MBq 177Lu-octreotate, while for our 
project, the mice were injected with 150 MBq 177Lu-octreotate. That article clearly states that 
the biodistribution is dependent on the injected activity; nevertheless, the resulting differences 





This work demonstrates pro-apoptotic regulation in cortical tissue after 177Lu-octreotate 
treatment and strongly advocates further analysis of the apoptotic fate in future studies. The 
results show a difference between the immediate response after one day and the prolonged 
response after seven days. The importance of the difference in absorbed dose and time after 
irradiation needs to be clarified in further studies, as well as a study of medullary tissue in order 
to assess the risk for the entire organ. 
The potential induction of apoptosis after treatment emphasises the importance of finding 
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Abl1 Positive regulation of apoptosis -1.198 1.006 
Aifm1 Caspase activation 1.002 1.114 
Akt1 
Anti-apoptotic, positive regulation of 
apoptosis 
-1.197 1.111 
Anxa5 Positive regulation of apoptosis -1.129 -1.027 
Apaf1 Caspase activation 2.216 1.407 
Api5 Anti-apoptotic -1.085 -1.033 
Atf5 Anti-apoptotic -1.266 -1.039 
Bad Pro-apoptotic -1.044 1.081 
Bag1 Negative regulation of apoptosis -1.046 1.095 
Bag3 Negative regulation of apoptosis -1.597 -1.065 
Bak1 Positive regulation of apoptosis -1.111 1.030 
Bax Pro-apoptotic, caspase activation 2.620 1.762 
Bcl10 




Anti-apoptotic, negative regulation of 
apoptosis 
-1.132 -1.555 
Bcl2a1a Negative regulation of apoptosis -1.295 -1.758 
Bcl2l1 




Anti-apoptotic, negative regulation of 
apoptosis, caspase activation 
3.821 1.283 
Bcl2l11 








Pro-apoptotic, positive regulation of 
apoptosis 
1.153 -1.044 
Birc2 Negative regulation of apoptosis -1.057 -1.129 
Birc3 
Anti-apoptotic, negative regulation of 
apoptosis 
1.116 -2.776 
Birc5 Anti-apoptotic, caspase inhibition -1.513 -1.129 
Bnip2 




Pro-apoptotic, anti-apoptotic, positive 
regulation of apoptosis, negative 
regulation of apoptosis 
-1.103 1.070 
Bnip3l 
Pro-apoptotic, anti-apoptotic, positive 
regulation of apoptosis, negative 
regulation of apoptosis 
-1.337 -1.378 
Bok Pro-apoptotic -1.773 1.015 
Card10 Negative regulation of apoptosis 1.139 -1.608 
Casp1 






Casp12 Pro-apoptotic, caspase 1.066 -1.175 
Casp14 
























Pro-apoptotic, positive regulation of 
apoptosis, caspase 
1.015 1.100 
Casp9 Caspase, caspase activation -1.014 1.002 
Cd40 Positive regulation of apoptosis 1.228 -1.060 
Cd40lg 








Extracellular apoptotic signals, anti-




DNA damage and repair, negative 
regulation of apoptosis 
-7.002 -1.392 
Cideb 
DNA damage and repair, positive 
regulation of apoptosis 
-1.249 1.284 
Cradd 
Death domain receptor, positive 
regulation of apoptosis 
-1.061 1.138 
Dad1 Anti-apoptotic 1.093 1.229 
Dapk1 
Extracellular apoptotic signals, death 




Pro-apoptotic, positive regulation of 
apoptosis 
1.142 1.103 
Dffb Pro-apoptotic 1.081 -1.060 
Diablo Pro-apoptotic 1.139 1.132 
Fadd 
Death domain receptor, positive 
regulation of apoptosis 
1.156 1.150 
Fas 
Pro-apoptotic, anti-apoptotic, negative 
regulation of apoptosis 
1.670 1.039 
Fasl 
Pro-apoptotic, positive regulation of 
apoptosis 
-1.401 -1.655 
Gadd45a Positive regulation of apoptosis -1.314 -1.044 
Igf1r Anti-apoptotic -1.192 1.063 
il10 Anti-apoptotic 1.308 1.604 
Lhx4 Anti-apoptotic - - 
Ltbr Positive regulation of apoptosis 1.086 1.119 









Anti-apoptotic, negative regulation of 
apoptosis 
1.186 -1.134 
Naip1 Anti-apoptotic 1.179 1.053 
Naip2 Anti-apoptotic -1.389 -1.642 
Nfkb1 Death domain receptor, anti-apoptotic -1.186 -1.058 
Nme5 Anti-apoptotic 1.027 1.064 
Nod1 
Pro-apoptotic, positive regulation of 
apoptosis, caspase activation 
-1.447 -1.036 
Nol3 
Anti-apoptotic, negative regulation of 
apoptosis 
-1.037 -1.449 
Polb Anti-apoptotic -1.074 -1.054 
Prdx2 Anti-apoptotic 1.036 1.032 
Pycard 
Pro-apoptotic, positive regulation of 
apoptosis, caspase activation 
1.113 -1.168 
Ripk1 Death domain receptor -1.083 -1.055 
Tnf 




Death domain receptor, positive 
regulation of apoptosis, caspase 
activation 
6.131 2.626 
Tnfrsf11b Death domain receptor -1.272 1.287 
Tnfrsf1a Death domain receptor -1.113 1.047 
Tnfsf10 
Pro-apoptotic, Positive regulation of 
apoptosis 
-1.546 -1.301 
Tnfsf12 Positive regulation of apoptosis -1.247 1.184 
Traf1 Positive regulation of apoptosis 1.050 -1.430 
Traf2 Positive regulation of apoptosis -1.063 -1.191 
Traf3 




DNA damage and reparation, negative 
regulation of apoptosis, positive 












DNA damage and reparation, negative 
regulation of apoptosis 
2.677 -1.087 
Xiap 
Anti-apoptotic, negative regulation of 
apoptosis, caspase inhibition 
-1.223 1.150 
Actb  Control gene - - 
B2m  Control gene - - 
Gapdh  Control gene - - 
Gusb  Control gene - - 
Hsp90ab1  Control gene - - 
